Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.

MLA

van der Wiel, Alexander M. A., et al. “Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.” Molecular Cancer Therapeutics, vol. 20, no. 12, Dec. 2021, pp. 2372–83. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-21-0406.

APA

van der Wiel, A. M. A., Jackson-Patel, V., Niemans, R., Yaromina, A., Liu, E., Marcus, D., Mowday, A. M., Lieuwes, N. G., Biemans, R., Lin, X., Fu, Z., Kumara, S., Jochems, A., Ashoorzadeh, A., Anderson, R. F., Hicks, K. O., Bull, M. R., Abbattista, M. R., Guise, C. P., … Lambin, P. (2021). Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506. Molecular Cancer Therapeutics, 20(12), 2372–2383. https://doi.org/10.1158/1535-7163.MCT-21-0406

Chicago

van der Wiel, Alexander M A, Victoria Jackson-Patel, Raymon Niemans, Ala Yaromina, Emily Liu, Damiënne Marcus, Alexandra M Mowday, et al. 2021. “Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.” Molecular Cancer Therapeutics 20 (12): 2372–83. doi:10.1158/1535-7163.MCT-21-0406.